Barclays Reaffirms Their Hold Rating on Bausch + Lomb Corporation (BLCO)

Barclays analyst Matt Miksic reiterated a Hold rating on Bausch + Lomb Corporation today and set a price target of $20.00.

Claim 30% Off TipRanks

• Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
• Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

According to TipRanks, Miksic is a 4-star analyst with an average return of 2.6% and a 50.42% success rate. Miksic covers the Healthcare sector, focusing on stocks such as Becton Dickinson, Abbott Laboratories, and Boston Scientific.

In addition to Barclays, Bausch + Lomb Corporation also received a Hold from Stifel Nicolaus’s Thomas Stephan in a report issued on April 7. However, on the same day, Citi reiterated a Buy rating on Bausch + Lomb Corporation (NYSE: BLCO).

Based on Bausch + Lomb Corporation’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $1.41 billion and a GAAP net loss of $58 million. In comparison, last year the company earned a revenue of $1.28 billion and had a GAAP net loss of $3 million

Based on the recent corporate insider activity of 65 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of BLCO in relation to earlier this year. Last month, Sam Eldessouky, the EVP & CFO of BLCO bought 4,000.00 shares for a total of $68,520.00.